CARM1 inhibition through TP-064 reduced DLBCL cell proliferation, with the highest efficacy being observed when cells carried inactivating CBP or p300 gene mutations [157], whereas treatment with EZM2302, a more bioavailable CARM1 inhibitor, reduced the amount of p300-mutated DLBCL cells in xenograft models and worked synergistically with p300/CBP inhibitors [157]. The gene discussed is CARM1; the disease is diffuse large B-cell lymphoma.